Publications

Journal Articles

  1. & Stability of proinsulin in whole blood. Clinical Biochemistry 52, 153-155.
  2. & Comparison of a point-of-care analyser for the determination of HbA1c with HPLC method. Practical Laboratory Medicine 8, 26-29.
  3. & Accuracy Evaluation of a Blood Glucose Monitoring System According to EN ISO 15197:2015. Journal of Diabetes Science and Technology 11(4), 849-850.
  4. & Retrospective analysis of newly recorded certifications of visual impairment due to diabetic retinopathy in Wales during 2007–2015. BMJ Open 7(7), e015024
  5. et. al. Metabolic and immune effects of immunotherapy with proinsulin peptide in human new-onset type 1 diabetes. Science Translational Medicine 9(402), eaaf7779
  6. & Self-monitoring of Blood Glucose in Non-Insulin Treated Type 2 Diabetes (The SMBG Study): study protocol for a randomised controlled trial. BMC Endocrine Disorders 17(1)
  7. & Stimulated urine C-peptide creatinine ratio vs serum C-peptide level for monitoring of β-cell function in the first year after diagnosis of Type 1 diabetes. Diabetic Medicine 33(11), 1564-1568.
  8. & Postmarket Approval Surveillance of a Low Acquisition Cost Blood Glucose Monitoring System. Journal of Diabetes Science and Technology 10(5), 1195-1196.
  9. & Postmarket Approval Surveillance of a Low Acquisition Cost Blood Glucose Monitoring System. Journal of Diabetes Science and Technology 10(5), 1195-1196.
  10. & Algorithm that delivers an individualized rapid-acting insulin dose after morning resistance exercise counters post-exercise hyperglycaemia in people with Type 1 diabetes. Diabetic Medicine 33(4), 506-510.
  11. & Diabetic Retinopathy in Newly Diagnosed Subjects With Type 2 Diabetes Mellitus: Contribution of β-Cell Function. The Journal of Clinical Endocrinology & Metabolism 101(2), 572-580.
  12. Can HbA1c detect undiagnosed diabetes in acute medical hospital admissions?. Diabetes Research and Clinical Practice
  13. & Diabetic Retinopathy in Newly Diagnosed Subjects With Type 2 Diabetes Mellitus: Contribution of β-Cell Function. The Journal of Clinical Endocrinology & Metabolism 101(2), 572-580.
  14. & HbA1cmeasurement and relationship to incident stroke. Diabetic Medicine, n/a-n/a.
  15. & Incidence and progression of diabetic retinopathy within a private diabetes mellitus clinic in South Africa. Journal of Endocrinology, Metabolism and Diabetes of South Africa 20(3), 127-133.
  16. & Incidence and progression of diabetic retinopathy within a private diabetes mellitus clinic in South Africa. Journal of Endocrinology, Metabolism and Diabetes of South Africa 20(3), 127-133.
  17. & Incidence and progression of diabetic retinopathy within a private diabetes mellitus clinic in South Africa. Journal of Endocrinology, Metabolism and Diabetes of South Africa 20(3), 127-133.
  18. & Evidence for a persistent, major excess in all cause admissions to hospital in children with type-1 diabetes: results from a large Welsh national matched community cohort study. BMJ Open 5(4), e005644-e005644.
  19. & Association between the preoperative fasting and postprandial C-peptide AUC with resolution of type 2 diabetes 6months following bariatric surgery. Metabolism 64(11), 1556-1563.
  20. & Bridging-type enzyme-linked immunoassay for zinc transporter 8 autoantibody measurements in adult patients with diabetes mellitus. Clinica Chimica Acta 447, 90-95.
  21. & Impact of single and multiple sets of resistance exercise in type 1 diabetes. Scandinavian Journal of Medicine & Science in Sports, n/a-n/a.
  22. & Reductions in resistance exercise-induced hyperglycaemic episodes are associated with circulating interleukin-6 in Type 1 diabetes. Diabetic Medicine 31(8), 1009-1013.
  23. & Metabolic Implications when Employing Heavy Pre- and Post-Exercise Rapid-Acting Insulin Reductions to Prevent Hypoglycaemia in Type 1 Diabetes Patients: A Randomised Clinical Trial. PLoS ONE 9(5), e97143
  24. & Comparison of IFCC-calibrated HbA1c from laboratory and point of care testing systems. Diabetes Research and Clinical Practice 105(3), 364-372.
  25. & Central arterial stiffness and diastolic dysfunction are associated with insulin resistance and abdominal obesity in young women but polycystic ovary syndrome does not confer additional risk. Human Reproduction 29(9), 2041-2049.
  26. et. al. Prevalence of diabetic retinopathy within a national diabetic retinopathy screening service. British Journal of Ophthalmology
  27. et. al. Does bariatric surgery adversely impact on diabetic retinopathy in persons with morbid obesity and type 2 diabetes? A pilot study. Journal of Diabetes and its Complications 28(2), 191-195.
  28. & A comparison of the pharmacodynamic profiles of insulin detemir and insulin glargine: A single dose clamp study in people with type 2 diabetes. Diabetes & Metabolism 39(6), 537-542.
  29. & Estimates of the relative and absolute diurnal contributions of fasting and post-prandial plasma glucose over a range of hyperglycaemia in type 2 diabetes. Diabetes & Metabolism 39(4), 337-342.
  30. et. al. Ethnic Differences in the Prevalence of Diabetic Retinopathy in Persons With Diabetes When First Presenting at a Diabetes Clinic in South Africa. Diabetes Care 36(2), 336-341.
  31. et. al. Effects of Nutritional Supplementation during Pregnancy on Early Adult Disease Risk: Follow Up of Offspring of Participants in a Randomised Controlled Trial Investigating Effects of Supplementation on Infant Birth Weight. PLoS ONE 8(12), e83371
  32. Turner, D., Ayles, M., Gray, B.J., Luzio, S., Bain, S.C., Rees, E.D., West, D.J., Campbell, M.D., Bastin, L., Bracken, R.M. Syncope during resistance exercise in an individual with type 1 diabetes. Practical Diabetes 30(7), 290-293.
  33. & Comparison of daytime 12-hour metabolic profiles after treatment with repaglinide and gliclazide in type 2 diabetes. Practical Diabetes 30(1), 27-32.
  34. & Comparison of daytime 12-hour metabolic profiles after treatment with repaglinide and gliclazide in type 2 diabetes. Practical Diabetes 30(1), 27-32.
  35. & Comparison of daytime 12-hour metabolic profiles after treatment with repaglinide and gliclazide in type 2 diabetes. Practical Diabetes 30(1), 27-32.
  36. & Incidence of diabetic retinopathy in people with type 2 diabetes mellitus attending the Diabetic Retinopathy Screening Service for Wales: retrospective analysis. BMJ 344(feb22 1), e874-e874.
  37. & Quantification of human serum insulin concentrations in clinical pharmacokinetic or bioequivalence studies: what defines the “best method”?. Clinical Chemistry and Laboratory Medicine 50(4), 663-666.
  38. & Diabetic retinopathy screening: perspectives of people with diabetes, screening intervals and costs of attending screening. Diabetic Medicine 29(7), 878-885.
  39. & Preferences of people with diabetes for diabetic retinopathy screening: a discrete choice experiment. Diabetic Medicine 29(7), 869-877.
  40. & Effects of initiation and titration of a single pre-prandial dose of insulin glulisine while continuing titrated insulin glargine in type 2 diabetes: a 6-month ‘proof-of-concept' study. Diabetes, Obesity and Metabolism 13(11), 1020-1027.
  41. & Impact of pre-exercise rapid-acting insulin reductions on ketogenesis following running in Type 1 diabetes. Diabetic Medicine 28(2), 218-222.
  42. et. al. Effects of short-term therapy with glibenclamide and repaglinide on incretin hormones and oxidative damage associated with postprandial hyperglycaemia in people with type 2 diabetes mellitus. Diabetes Research and Clinical Practice 94(2), 199-206.
  43. & The effect of a supported exercise programme in patients with newly diagnosed Type 2 diabetes: A pilot study. Journal of Sports Sciences 29(6), 579-586.
  44. et. al. A combined insulin reduction and carbohydrate feeding strategy 30 min before running best preserves blood glucose concentration after exercise through improved fuel oxidation in type 1 diabetes mellitus. Journal of Sports Sciences 29(3), 279-289.
  45. & Comparative pharmacodynamic and pharmacokinetic characteristics of subcutaneous insulin glulisine and insulin aspart prior to a standard meal in obese subjects with type 2 diabetes. Diabetes, Obesity and Metabolism 13(3), 251-257.
  46. et. al. Isomaltulose Improves Postexercise Glycemia by Reducing CHO Oxidation in T1DM. Medicine & Science in Sports & Exercise 43(2), 204-210.
  47. et. al. Exercise-induced hyperglycaemia in the absence of diabetes. Diabetic Medicine 27(6), 723-724.
  48. & Impending Hyperglycemia in Normoglycemic Renal Transplant Recipients—An Experimental Predictive Surrogate. Transplantation 89(11), 1341-1346.
  49. & Daytime variability of postprandial glucose tolerance and pancreatic B-cell function using 12-h profiles in persons with Type 2 diabetes. Diabetic Medicine 27(3), 266-273.
  50. & Comparison of Rival Metabolic Syndrome Classifications Against Pathophysiological Markers in Renal Transplant Recipients. Transplantation 89(3), 347-352.
  51. et. al. Insulin Resistance Indexes in Renal Transplant Recipients Maintained on Tacrolimus Immunosuppression. Transplantation 89(3), 327-333.
  52. & Metformin Reduces Arterial Stiffness and Improves Endothelial Function in Young Women with Polycystic Ovary Syndrome: A Randomized, Placebo-Controlled, Crossover Trial. The Journal of Clinical Endocrinology & Metabolism 95(2), 722-730.
  53. & The glucose lowering effect of an oral insulin (Capsulin) during an isoglycaemic clamp study in persons with type 2 diabetes. Diabetes, Obesity and Metabolism 12(1), 82-87.
  54. & Relative and absolute contributions of postprandial and fasting plasma glucose to daytime hyperglycaemia and HbA1cin subjects with Type 2 diabetes. Diabetic Medicine 26(10), 974-980.
  55. et. al. GADA testing: The current state of knowledge. Primary Care Diabetes 3(3), 189-191.
  56. et. al. Complex Interplay Between Insulinemia, Glycemia, and Glomerular Filtration Rate in Nondiabetic Renal Transplant Recipients. Transplantation 88(2), 290-292.
  57. & Use of Intraoperative Insulin Assay for the Localisation of Insulinoma. World Journal of Surgery 33(5), 969-971.
  58. et. al. The Effect of Rosuvastatin on Insulin Sensitivity and Pancreatic Beta-Cell Function in Nondiabetic Renal Transplant Recipients. American Journal of Transplantation 9(6), 1439-1445.
  59. & Insulin Hyposecretion in Nondiabetic, Tacrolimus-Treated Renal Transplant Recipients More Than 6 months Posttransplantation. Transplantation 87(12), 1870-1876.
  60. & Insulin Hyposecretion in Nondiabetic, Tacrolimus-Treated Renal Transplant Recipients More Than 6 months Posttransplantation. Transplantation 87(12), 1870-1876.
  61. & Insulin Hyposecretion in Nondiabetic, Tacrolimus-Treated Renal Transplant Recipients More Than 6 months Posttransplantation. Transplantation 87(12), 1870-1876.
  62. Simultaneous trend analysis for evaluating outcomes in patient-centred health monitoring services. Health Care Manag Sci. 11(2), 152-166.
  63. & A comparison of preprandial insulin glulisine versus insulin lispro in people with Type 2 diabetes over a 12-h period. Diabetes Research and Clinical Practice 79(2), 269-275.
  64. & Errata. Diabetes Care 31(1), 188-188.
  65. & Errata. Diabetes Care 31(1), 188-188.
  66. & Errata. Diabetes Care 31(1), 188-188.
  67. & Comparison of Pharmacokinetics and Dynamics of the Long-Acting Insulin Analogs Glargine and Detemir at Steady State in Type 1 Diabetes: A double-blind, randomized, crossover study. Diabetes Care 30(10), 2447-2452.
  68. & Insulin Resistance and inflammation—A Further Systemic Complication of COPD. COPD: Journal of Chronic Obstructive Pulmonary Disease 4(2), 121-126.
  69. & Comparison of Pharmacokinetics and Dynamics of the Long-Acting Insulin Analogs Glargine and Detemir at Steady State in Type 1 Diabetes: A double-blind, randomized, crossover study. Diabetes Care 30(10), 2447-2452.
  70. & Insulin Resistance and inflammation—A Further Systemic Complication of COPD. COPD: Journal of Chronic Obstructive Pulmonary Disease 4(2), 121-126.
  71. & Comparison of Pharmacokinetics and Dynamics of the Long-Acting Insulin Analogs Glargine and Detemir at Steady State in Type 1 Diabetes: A double-blind, randomized, crossover study. Diabetes Care 30(10), 2447-2452.
  72. & Insulin Resistance and inflammation—A Further Systemic Complication of COPD. COPD: Journal of Chronic Obstructive Pulmonary Disease 4(2), 121-126.
  73. Luzio, S.D., Owens, D.R. Update on progress with oral insulin. 24
  74. Luzio, S., Piehlmeier, W., Tovar, C., Eberl, S., Lätzsch, G., Fallböhmer, E., Rumpel, E., Owens, D.R., Landgraf, R. Results of the pilot study of DIADEM—A comprehensive disease management programme for type 2 diabetes. Diabetes Research and Clinical Practice 76(3), 410-417.
  75. Manley, S.E., Stratton, I.M., Clark, P.M., Luzio, S.D. Comparison of 11 Human Insulin Assays: Implications for Clinical Investigation and Research. Clinical Chemistry 53(5), 922-932.
  76. Luzio, S., Dunseath, G., Peter, R., Pauvaday, V., Owens, D.R. Comparison of the pharmacokinetics and pharmacodynamics of biphasic insulin aspart and insulin glargine in people with type 2 diabetes. Diabetologia 49(6), 1163-1168.
  77. & Relationship between HbA1c and indices of glucose tolerance derived from a standardized meal test in newly diagnosed treatment naive subjects with Type 2 diabetes. Diabetic Medicine 23(9), 990-995.
  78. & The systemic inflammatory response to exercise in adults with cystic fibrosis. Journal of Cystic Fibrosis 5(2), 105-112.
  79. & Relationship between HbA1c and indices of glucose tolerance derived from a standardized meal test in newly diagnosed treatment naive subjects with Type 2 diabetes. Diabetic Medicine 23(9), 990-995.
  80. & The systemic inflammatory response to exercise in adults with cystic fibrosis. Journal of Cystic Fibrosis 5(2), 105-112.
  81. & Relationship between HbA1c and indices of glucose tolerance derived from a standardized meal test in newly diagnosed treatment naive subjects with Type 2 diabetes. Diabetic Medicine 23(9), 990-995.
  82. & The systemic inflammatory response to exercise in adults with cystic fibrosis. Journal of Cystic Fibrosis 5(2), 105-112.
  83. Ollerton, R.L., Luzio, S.D., Owens, D.R. Contribution of fasting and postprandial plasma glucose to HbA1c [2]. 22
  84. Cozma, L.S., Luzio, S.D., Dunseath, G.J., Underwood, P.M., Owens, D.R. -Cell Response During a Meal Test: A comparative study of incremental doses of repaglinide in type 2 diabetic patients. Diabetes Care 28(5), 1001-1007.
  85. Schneider, S., Aldington, S.J., Kohner, E.M., Luzio, S., Owens, D.R., Schmidt, V., Schuell, H., Zahlmann, G. Quality assurance for diabetic retinopathy telescreening. Diabetic Medicine 22(6), 794-802.
  86. Peter, R., Luzio, S.D., Dunseath, G., Miles, A., Hare, B., Backx, K., Pauvaday, V., Owens, D.R. Effects of Exercise on the Absorption of Insulin Glargine in Patients With Type 1 Diabetes. Diabetes Care 28(3), 560-565.
  87. Luzio, S., Tovar, C., Piehlmeier, W., Eberl, S., Lätzsch, G., Fallböhmer, E., Evans, J., Owens, D.R., Wollersheim, T., Bausch, F., Rupprecht, C., Schmidt, V., Rumpel, E., Mankopf, M., Christ, T., Jähnichen-Stöcker, H., Landgraf, R. DIADEM: implementation of a comprehensive disease management programme for type 2 diabetes. Practical Diabetes International 22(3), 93-97.
  88. Erichsen, L., Agbaje, O.F., Luzio, S.D., Owens, D.R., Hovorka, R. Population and individual minimal modeling of the frequently sampled insulin-modified intravenous glucose tolerance test. Metabolism 53(10), 1349-1354.
  89. Luzio, S., Hatcher, S., Zahlmann, G., Mazik, L., Morgan, M., Liesenfeld, B., Bek, T., Schuell, H., Schneider, S., Owens, D.R., Kohner, E. Feasibility of using the TOSCA telescreening procedures for diabetic retinopathy. Diabetic Medicine 21(10), 1121-1128.
  90. Luzio, S.D., George, L., Beck, P., Chester, P., Owens, D.R. The pharmacokinetics of s.c. Semitard MC, human NPH ge, Rapitard MC and human NPH 30:70 ge insulin in healthy, non-diabetic subjects. European Journal of Internal Medicine 14(2), 107-112.
  91. Luzio, S.D., Beck, P., Owens, D.R. Comparison of the Subcutaneous Absorption of Insulin Glargine (Lantus®) and NPH Insulin in Patients with Type 2 Diabetes. Hormone and Metabolic Research 35(7), 434-438.
  92. Agbaje, O.F., Luzio, S.D., Albarrak, A.I.S., Lunn, D.J., Owens, D.R., Hovorka, R. Bayesian hierarchical approach to estimate insulin sensitivity by minimal model. Clinical Science 105(5), 551-560.
  93. Ionescu, A.A., Nixon, L.S., Luzio, S., Lewis-Jenkins, V., Evans, W.D., Stone, M.D., Owens, D.R., Routledge, P.A., Shale, D.J. Pulmonary function, body composition, and protein catabolism in adults with cystic fibrosis. 165
  94. Mehring, G.H., Coates, P.A., Brunel, P.C., Luzio, S.D., Owens, D.R. Insulin sensitivity in Type 2 diabetes: univariate and multivariate techniques to derive estimates of insulin sensitivity from the insulin modified intravenous glucose tolerance test (FSIGT). Computer Methods and Programs in Biomedicine 68(2), 161-176.
  95. Owens, D.R., Cozma, L.S., Luzio, S.D. Early-phase prandial insulin secretion: its role in the pathogenesis of type 2 diabetes mellitus and its modulation by repaglinide.. 15
  96. Cozma, L.S., Luzio, S.D., Dunseath, G.J., Langendorg, K.W., Pieber, T., Owens, D.R. Comparison of the Effects of Three Insulinotropic Drugs on Plasma Insulin Levels After a Standard Meal. Diabetes Care 25(8), 1271-1276.
  97. Albarrak, A.I., Luzio, S.D., Chassin, L.J., Playle, R.A., Owens, D.R., Hovorka, R. Associations of Glucose Control with Insulin Sensitivity and Pancreatic  -Cell Responsiveness in Newly Presenting Type 2 Diabetes. Journal of Clinical Endocrinology & Metabolism 87(1), 198-203.
  98. Luzio, S.D., Dunseath, G., Owens, D.R. Acute Effects of Valsartan on Insulin Sensitivity in Obese, Non-Hypertensive Subjects with and without Type 2 Diabetes. Hormone and Metabolic Research 34(5), 271-274.
  99. Hovorka, R., Albarrak, A., Chassin, L., Luzio, S.D., Playle, R., Owens, D.R. Relationship between β-cell responsiveness and fasting plasma glucose in Caucasian subjects with newly presenting Type 2 diabetes. Diabetic Medicine 18(10), 797-802.
  100. Luzio, S.D., Lucas, I., Owens, D.R. Importance of Validation of Immunoassays for Intact Proinsulin. Clinical Chemistry and Laboratory Medicine 39(7)
  101. Luzio, S.D., Anderson, D.M., Owens, D.R. Effects of Timing of Administration and Meal Composition on the Pharmacokinetic and Pharmacodynamic Characteristics of the Short-Acting Oral Hypoglycemic Agent Nateglinide in Healthy Subjects. Journal of Clinical Endocrinology & Metabolism 86(10), 4874-4880.
  102. Owens, D.R., Coates, P.A., Luzio, S.D., Tinbergen, J.P., Kurzhals, R. Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: Comparison with NPH insulin and the influence of different subcutaneous injection sites. 23
  103. Owens, D.R., Luzio, S.D., Ismail, I., Bayer, T. Increased prandial insulin secretion after administration of a single preprandial oral dose of repaglinide in patients with type 2 diabetes. 23
  104. & Day-to-day variability of fasting plasma glucose in newly diagnosed type 2 diabetic subjects. Diabetes Care 22
  105. & Underdiagnosis of type 2 diabetes by use of American Diabetes Association criteria [5]. Diabetes Care 22
  106. & Day-to-day variability of fasting plasma glucose in newly diagnosed type 2 diabetic subjects. Diabetes Care 22
  107. & Underdiagnosis of type 2 diabetes by use of American Diabetes Association criteria [5]. Diabetes Care 22
  108. & Day-to-day variability of fasting plasma glucose in newly diagnosed type 2 diabetic subjects. Diabetes Care 22
  109. & Underdiagnosis of type 2 diabetes by use of American Diabetes Association criteria [5]. Diabetes Care 22
  110. & Determining true glomerular filtration status in newly presenting type 2 diabetic subjects using age and sex adjustment. Diabetes Care 21(11), 1893-1896.
  111. & Determining true glomerular filtration status in newly presenting type 2 diabetic subjects using age and sex adjustment. Diabetes Care 21(11), 1893-1896.
  112. & Determining true glomerular filtration status in newly presenting type 2 diabetic subjects using age and sex adjustment. Diabetes Care 21(11), 1893-1896.
  113. Hovorka, R., Chassin, L., Luzio, S.D., Playle, R., Owens, D.R. Pancreatic  -Cell Responsiveness during Meal Tolerance Test: Model Assessment in Normal Subjects and Subjects with Newly Diagnosed Noninsulin-Dependent Diabetes Mellitus. Journal of Clinical Endocrinology & Metabolism 83(3), 744-750.
  114. Owens, D.R., Luzio, S.D. Designer insulins. 37
  115. Owens, D.R., Luzio, S.D., Coates, P.A. Insulin secretion and sensitivity in newly diagnosed NIDDM caucasians in the UK. 13
  116. Nguyen, H.T., Luzio, S.D., Dolben, J., West, J., Beck, L., Coates, P.A., Owens, D.R. Dominant risk factors for retinopathy at clinical diagnosis in patients with type II diabetes mellitus. Journal of Diabetes and its Complications 10(4), 211-219.
  117. & A new breakfast cereal containing guar gum reduces postprandial plasma glucose and insulin concentrations in normal-weight human subjects. British Journal of Nutrition 76
  118. & Erratum: The hypoglycaemic properties of a novel phenylalanine derivative in healthy subjects (Practical Diabetes International (1996) 13 (139)). Practical Diabetes International 13
  119. & Proinsulin secretion during the first 3 years after diagnosis in diabetic patients with and without islet cell antibodies. Diabetes Care 19
  120. & A new breakfast cereal containing guar gum reduces postprandial plasma glucose and insulin concentrations in normal-weight human subjects. British Journal of Nutrition 76
  121. & Erratum: The hypoglycaemic properties of a novel phenylalanine derivative in healthy subjects (Practical Diabetes International (1996) 13 (139)). Practical Diabetes International 13
  122. & Proinsulin secretion during the first 3 years after diagnosis in diabetic patients with and without islet cell antibodies. Diabetes Care 19
  123. & A new breakfast cereal containing guar gum reduces postprandial plasma glucose and insulin concentrations in normal-weight human subjects. British Journal of Nutrition 76
  124. & Erratum: The hypoglycaemic properties of a novel phenylalanine derivative in healthy subjects (Practical Diabetes International (1996) 13 (139)). Practical Diabetes International 13
  125. & Proinsulin secretion during the first 3 years after diagnosis in diabetic patients with and without islet cell antibodies. Diabetes Care 19
  126. Coates, P.A., Ismail, I.S., Luzio, S.D., Griffiths, I., Ollerton, R.L., Volund, A., Owens, D.R. Intranasal insulin: The effects of three dose regimens on postprandial glycaemic profiles in type lI diabetic subjects. 12
  127. Coates, P.A., Luzio, S.D., Brunel, P., Owens, D.R. Comparison of estimates of insulin sensitivity from minimal model analysis of the insulin-modified frequently sampled intravenous glucose tolerance test and the isoglycemic hyperinsulinemic clamp in subjects with NIDDM. 44
  128. Godsland, I.F., Luzio, S., Wynn, V., Owens, D.R. Methodological issues in the application of the minimal model: effects of glucose dose, basal glucose concentration, test duration and modelling constraint.. 26
  129. Dean, J.D., Matthews, S.B., Dolben, J., Carolan, G., Luzio, S., Owens, D.R. Cholesterol rich apo B containing lipoproteins and smoking are independently associated with macrovascular disease in normotensive NIDDM patients. 11
  130. Shannon, A.G., Hogg, J.M., Ollerton, R.L., Luzio, S., Owens, D.R. A mathematical model of insulin secretion. 11
  131. Coates, P.A., Ollerton, R.L., Luzio, S.D., Ismail, I., Owens, D.R. A glimpse of the ‘natural history’ of established Type 2 (non-insulin dependent) diabetes mellitus from the spectrum of metabolic and hormonal responses to a mixed meal at the time of diagnosis. Diabetes Research and Clinical Practice 26(3), 177-187.
  132. Owens, D.R., Jones, A.L., Dolben, J., Dean, J.D., Petocz, P., Coates, P.A., Luzio, S.D. The pharmacokinetics of five pre-mixed combinations of 'short-' and 'intermediate-acting' (NPH) insulins in healthy subjects following subcutaneous administration.. 22
  133. Coates, P.A., Ollerton, R.L., Luzio, S.D., Ismail, I.S., Owens, D.R. Reduced sampling protocols in estimation of insulin sensitivity and glucose effectiveness using the minimal model in NIDDM. 42
  134. Atiea, J.A., Luzio, S., Owens, D.R. The dawn phenomenon and diabetes control in treated NIDDM and IDDM patients. Diabetes Research and Clinical Practice 16(3), 183-190.
  135. & Miglitol: A new alpha-glucosidase inhibitor decreases post-prandial glucose excursions. British Journal of Clinical Pharmacology 33
  136. & Single dose-response study of a new oral hypoglycaemic agent in diet-treated patients with non-insulin-dependent diabetes mellitus (NIDDM). British Journal of Clinical Pharmacology 34
  137. & Miglitol: A new alpha-glucosidase inhibitor decreases post-prandial glucose excursions. British Journal of Clinical Pharmacology 33
  138. & Single dose-response study of a new oral hypoglycaemic agent in diet-treated patients with non-insulin-dependent diabetes mellitus (NIDDM). British Journal of Clinical Pharmacology 34
  139. & Miglitol: A new alpha-glucosidase inhibitor decreases post-prandial glucose excursions. British Journal of Clinical Pharmacology 33
  140. & Single dose-response study of a new oral hypoglycaemic agent in diet-treated patients with non-insulin-dependent diabetes mellitus (NIDDM). British Journal of Clinical Pharmacology 34
  141. & Intravenous insulin simulates early insulin peak and reduces post-prandial hyperglycaemia/ hyperinsulinaemia in type 2 (non-insulin-dependent) diabetes mellitus. Diabetes Research 16
  142. & Nitrendipine once or twice daily in hypertensive non-insulin-dependent diabetes mellitus. Journal of Cardiovascular Pharmacology 18
  143. & Intravenous insulin simulates early insulin peak and reduces post-prandial hyperglycaemia/ hyperinsulinaemia in type 2 (non-insulin-dependent) diabetes mellitus. Diabetes Research 16
  144. & Nitrendipine once or twice daily in hypertensive non-insulin-dependent diabetes mellitus. Journal of Cardiovascular Pharmacology 18
  145. & Intravenous insulin simulates early insulin peak and reduces post-prandial hyperglycaemia/ hyperinsulinaemia in type 2 (non-insulin-dependent) diabetes mellitus. Diabetes Research 16
  146. & Nitrendipine once or twice daily in hypertensive non-insulin-dependent diabetes mellitus. Journal of Cardiovascular Pharmacology 18
  147. Atiea, J.A., Aslan, S.M., Owens, D.R., Luzio, S. Early morning hyperglycaemia "dawn phenomenon" in non-insulin dependent diabetes mellitus (NIDDM): effects of cortisol suppression by metyrapone.. 14
  148. Morgan, R., Bishop, A., Owens, D.R., Luzio, S.D., Peters, J.R., Rees, A. Allelic variants at insulin-receptor and insulin gene loci and susceptibility to NIDDM in Welsh population. 39
  149. & A supplementary infusion of glucose-dependent insulinotropic polypeptide (GIP) with a meal does not significantly improve the β cell response or glucose tolerance in type 2 diabetes mellitus. Diabetes Research and Clinical Practice 7(4), 263-269.
  150. & Glucose dependent insulinotropic polypeptide (GIP) infused intravenously is insulinotropic in the fasting state in type 2 (non-insulin dependent) diabetes mellitus. Hormone and Metabolic Research 21
  151. & Hormonal and glycaemic responses to serial meals in newly diagnosed non insulin dependent diabetic patients. Diabete et Metabolisme 15
  152. & INSULIN DEFICIENCY IN NON-INSULIN-DEPENDENT DIABETES. The Lancet 333(8633), 293-295.
  153. & Obesity is associated with increased post-prandial GIP levels which are not reduced by dietary restriction and weight loss. Diabete et Metabolisme 15
  154. & Sensitive and specific two-site immunoradiometric assays for human insulin, proinsulin, 65-66 split and 32-33 split proinsulins. Biochemical Journal 260
  155. & Serial glucose tolerance assessment during cyclosporine therapy. Transplantation Proceedings 21
  156. & The glucose dependent insulinotropic polypeptide response to oral glucose and mixed meals is increased in patients with Type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 32(9)
  157. & A supplementary infusion of glucose-dependent insulinotropic polypeptide (GIP) with a meal does not significantly improve the β cell response or glucose tolerance in type 2 diabetes mellitus. Diabetes Research and Clinical Practice 7(4), 263-269.
  158. & Glucose dependent insulinotropic polypeptide (GIP) infused intravenously is insulinotropic in the fasting state in type 2 (non-insulin dependent) diabetes mellitus. Hormone and Metabolic Research 21
  159. & Hormonal and glycaemic responses to serial meals in newly diagnosed non insulin dependent diabetic patients. Diabete et Metabolisme 15
  160. & INSULIN DEFICIENCY IN NON-INSULIN-DEPENDENT DIABETES. The Lancet 333(8633), 293-295.
  161. & Obesity is associated with increased post-prandial GIP levels which are not reduced by dietary restriction and weight loss. Diabete et Metabolisme 15
  162. & Sensitive and specific two-site immunoradiometric assays for human insulin, proinsulin, 65-66 split and 32-33 split proinsulins. Biochemical Journal 260
  163. & Serial glucose tolerance assessment during cyclosporine therapy. Transplantation Proceedings 21
  164. & The glucose dependent insulinotropic polypeptide response to oral glucose and mixed meals is increased in patients with Type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 32(9)
  165. & A supplementary infusion of glucose-dependent insulinotropic polypeptide (GIP) with a meal does not significantly improve the β cell response or glucose tolerance in type 2 diabetes mellitus. Diabetes Research and Clinical Practice 7(4), 263-269.
  166. & Glucose dependent insulinotropic polypeptide (GIP) infused intravenously is insulinotropic in the fasting state in type 2 (non-insulin dependent) diabetes mellitus. Hormone and Metabolic Research 21
  167. & Hormonal and glycaemic responses to serial meals in newly diagnosed non insulin dependent diabetic patients. Diabete et Metabolisme 15
  168. & INSULIN DEFICIENCY IN NON-INSULIN-DEPENDENT DIABETES. The Lancet 333(8633), 293-295.
  169. & Obesity is associated with increased post-prandial GIP levels which are not reduced by dietary restriction and weight loss. Diabete et Metabolisme 15
  170. & Sensitive and specific two-site immunoradiometric assays for human insulin, proinsulin, 65-66 split and 32-33 split proinsulins. Biochemical Journal 260
  171. & Serial glucose tolerance assessment during cyclosporine therapy. Transplantation Proceedings 21
  172. & The glucose dependent insulinotropic polypeptide response to oral glucose and mixed meals is increased in patients with Type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 32(9)
  173. & Non-insulin-dependent diabetic patients (NIDDMs) do not demonstrate the dawn phenomenon at presentation. Diabetes Research and Clinical Practice 5(1), 37-44.
  174. & Retinopathy in newly presenting non-insulin-dependent (type 2) diabetic patients. Diabetes Research 9
  175. & Soluble and Lente human insulin mixtures in normal man. Diabetes Research 7
  176. & Non-insulin-dependent diabetic patients (NIDDMs) do not demonstrate the dawn phenomenon at presentation. Diabetes Research and Clinical Practice 5(1), 37-44.
  177. & Retinopathy in newly presenting non-insulin-dependent (type 2) diabetic patients. Diabetes Research 9
  178. & Soluble and Lente human insulin mixtures in normal man. Diabetes Research 7
  179. & Non-insulin-dependent diabetic patients (NIDDMs) do not demonstrate the dawn phenomenon at presentation. Diabetes Research and Clinical Practice 5(1), 37-44.
  180. & Retinopathy in newly presenting non-insulin-dependent (type 2) diabetic patients. Diabetes Research 9
  181. & Soluble and Lente human insulin mixtures in normal man. Diabetes Research 7
  182. Owens, D.R., Vora, J.P., Birtwell, J., Luzio, S., Hayes, T.M. The influence of aprotinin on regional absorption of soluble human insulin. 25
  183. Owens, D.R., Vora, J.P., Tronier, B., Keller, U., Luzio, S., Turkes, A. Hormonal counterregulatory responses to human (semi-synthetic and recombinant DNA) and porcine insulin induced hypoglycaemia. 8
  184. Vora, J., Owens, D.R., Luzio, S., Atiea, J., Ryder, R., Hayes, T.M. Renal response to intravenous somatostatin in insulin-dependent diabetic patients and normal subjects. 64
  185. Atiea, J.A., Ryder, R.R.J., Vora, J., Owens, D.R., Luzio, S.D., Williams, S., Hayes, T.M. Dawn phenomenon: Its frequency in non-insulin-dependent diabetic patients on conventional therapy. 10
  186. & The effects of glucose-dependent insulinotropic polypeptide infused at physiological concentrations in normal subjects and Type 2 (non-insulin-dependent) diabetic patients on glucose tolerance and B-cell secretion. Diabetologia 30(9), 707-712.
  187. & The effects of glucose-dependent insulinotropic polypeptide infused at physiological concentrations in normal subjects and Type 2 (non-insulin-dependent) diabetic patients on glucose tolerance and B-cell secretion. Diabetologia 30(9), 707-712.
  188. & The effects of glucose-dependent insulinotropic polypeptide infused at physiological concentrations in normal subjects and Type 2 (non-insulin-dependent) diabetic patients on glucose tolerance and B-cell secretion. Diabetologia 30(9), 707-712.
  189. & A comparison of the uptake of human and porcine insulins given intraperitoneally to patients with diabetes mellitus on continuous ambulatory peritoneal dialysis. Diabetes Research 3
  190. & A comparison of the uptake of human and porcine insulins given intraperitoneally to patients with diabetes mellitus on continuous ambulatory peritoneal dialysis. Diabetes Research 3
  191. & A comparison of the uptake of human and porcine insulins given intraperitoneally to patients with diabetes mellitus on continuous ambulatory peritoneal dialysis. Diabetes Research 3
  192. Owens, D.R., Vora, J., Morris, T., Luzio, S., Ryder, R.E., Atiea, J., Hayes, T.M. The metabolic response to glucagon and glucagon-(1-21)-peptide in normal subjects and non insulin dependent diabetics. 22
  193. Owens, D.R., Vora, J.P., Heding, L.G., Luzio, S., Ryder, R.E., Atiea, J., Hayes, T.M. Human, porcine and bovine ultralente insulin: Subcutaneous administration in normal man. 3
  194. Vora, J.P., Owens, D.R., Ryder, R., Atiea, J., Luzio, S., Hayes, T.M. Effect of somatostatin on renal function. 292
  195. & Study of porcine and human isophane (NPH) insulins in normal subjects. Diabetologia 26(4)
  196. & Study of porcine and human isophane (NPH) insulins in normal subjects. Diabetologia 26(4)
  197. & Study of porcine and human isophane (NPH) insulins in normal subjects. Diabetologia 26(4)
  198. & Human pancreatic transplantation--preliminary studies of carbohydrate control.. Transplantation Proceedings 13
  199. & Human pancreatic transplantation--preliminary studies of carbohydrate control.. Transplantation Proceedings 13
  200. & Human pancreatic transplantation--preliminary studies of carbohydrate control.. Transplantation Proceedings 13
  201. & Indirect two-site immunoradiometric assay of rat and mouse proinsulin. Diabetologia 17(4), 235-242.
  202. & Measurement of human proinsulin by an indirect two-site immunoradiometric assay. Diabetologia 17(4), 229-234.
  203. & Indirect two-site immunoradiometric assay of rat and mouse proinsulin. Diabetologia 17(4), 235-242.
  204. & Measurement of human proinsulin by an indirect two-site immunoradiometric assay. Diabetologia 17(4), 229-234.
  205. & Indirect two-site immunoradiometric assay of rat and mouse proinsulin. Diabetologia 17(4), 235-242.
  206. & Measurement of human proinsulin by an indirect two-site immunoradiometric assay. Diabetologia 17(4), 229-234.

Conference Contributions

  1. & (2015). Design of continuous non-invasive blood glucose monitoring sensor based on a microwave split ring resonator. Presented at Conference Proceedings - 2014 IEEE MTT-S International Microwave Workshop Series on: RF and Wireless Technologies for Biomedical and Healthcare Applications, IMWS-Bio 2014, doi:10.1109/IMWS-BIO.2014.7032398
  2. & (2015). Design of continuous non-invasive blood glucose monitoring sensor based on a microwave split ring resonator. Presented at Conference Proceedings - 2014 IEEE MTT-S International Microwave Workshop Series on: RF and Wireless Technologies for Biomedical and Healthcare Applications, IMWS-Bio 2014, doi:10.1109/IMWS-BIO.2014.7032398
  3. & (2015). Design of continuous non-invasive blood glucose monitoring sensor based on a microwave split ring resonator. Presented at Conference Proceedings - 2014 IEEE MTT-S International Microwave Workshop Series on: RF and Wireless Technologies for Biomedical and Healthcare Applications, IMWS-Bio 2014, doi:10.1109/IMWS-BIO.2014.7032398
  4. Subramanian, M., Conley, E.C., Rana, O.F., Hardisty, A., Ali, S., Luzio, S., Owens, D.R., Wright, S., Donovan, T., Bedi, B., Conway-Jones, D., Vyvyan, D., Arnold, G., Creasey, C., Horgan, A., Cox, T., Waite, R. (2008). Novel sensor technology integration for outcome-based risk analysis in diabetes.
  5. Ali, A.S., F.rana, O., Hardisty, A., Subramanian, M., Luzio, S., Owens, D.R., Conley, E.C. (2007). Portal technologies for patient-centred Integrated Care.
  6. Nguyen, H.T., Coates, P., Luzio, S., Owens, D.R. (1996). Reduced sampling protocol for the identification of insulin sensitivity.